Nucleonics
With Allowance of US Patent Application, Veritas Aims to Outlicense RNAi Delivery Technology
Premium
Veritas Bio, a biotechnology holding company established by two co-founders of expressed RNAi firm Nucleonics, said this week that the US Patent and Trademark Office has issued a notice of allowance on a patent application covering a novel liver-directed RNAi delivery technology.
With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.
Although it was one of the earliest patents in the RNAi field, the IP had earlier been deemed invalid by the USPTO after re-examination proceedings were initiated by now-defunct expressed RNAi firm Nucleonics.
Nov 11, 2010
Jan 21, 2010